Acambis news from FierceBiotech
NewsAcambis lands $425M smallpox vaccine contract
The U.K.'s Acambis has won a $425 million contract to supply the CDC with its smallpox vaccine for 10 years. Acambis will establish a U.S.-based manufacturing capability for ACAM2000 and deliver a Read more...
Sanofi buys into Acambis' West Nile vaccine program
Sanofi Pasteur is buying into Acambis' program for a novel West Nile vaccine. Read more...
ALSO NOTED: Teva invests in stem cell start-up; Anacor files for IPO; Merrion sets terms; and much more...
> Teva is investing $1 million in the stem cell start-up Cell Cure Neurosciences. Report > Anacor Read more...
Acambis' universal vaccine begins human clinical trials
Acambis is putting its universal vaccine approach to influenza to the test as it launches a Read more...
C&L: Altus tapped as new ImpactRx CEO
ImpactRx has named Richard C. Altus as president and CEO. Hemispherx Biopharma has hired Anthony A. Bonelli as president and COO. Bioenvision has named James S. Scibetta to the post of CFO. Adnexus Therapeutics has expanded its management team with the appointment of Bruce A. … Read more...ALSO NOTED: Aegera raises $21 million; M&A activity soars; and much more...> Canada's Aegera Therapeutics has raised $21 million in the first close of its third round of financing. The round includes $14 million in venture equity and $7 million in venture debt. Report > Metrics: There have been $16.6 billion worth of mergers and acquisitions in biotech since July, compared to $2.6 billion in the first half of the year. … Read more...Acambis shares plunge after U.S. nixes contractShares of Acambis took a beating after the company announced it was no longer in the competition for a U.S. contract to provide smallpox vaccine. Its stock plunged 39 percent after company officials said it was no longer being considered. Acambis said that it would arrange a meeting with government officials to "seek clarification." "We are surprised that the U.S. government would eliminate Acambis," CEO Gordon Cameron said. "We believe that our proposal would have met the … Read more...ALSO NOTED: Europe expands Synvisc approval; FDA issues "approvable" letter for paliperidone; and much more...> European regulators have agreed to expand the approval of Genzyme's Synvisc to include osteoarthritis of the ankle and shoulder. Report > J&J says its subsidiary has received an approvable letter from the FDA for paliperidone as a therapy for schizophrenia. But the drug maker did not say what issues were still left to be resolved. … Read more...ALSO NOTED: WiCell may offer stem cell lines; Medivir inks new pact; and much more...> The WiCell Research Institute in Madison, WI says it will make new embryonic stem cell lines created by Advanced Cell Technologies available to researchers if the feds agree to expand funding for them. ACT had announced, amid considerable controversy, that it had developed a technique to create new lines without destroying the embryo. Given the Bush administration's quick … Read more...ALSO NOTED: Allos gains orphan status for cancer therapy; NICE recommends against Velcade; and much more...> Allos Therapeutics has gained orphan drug status for an experimental cancer therapy. Report > The U.K.'s drug watchdog, the National Institute for Health and Clinical Excellence, has recommended against covering Velcade, saying its effectiveness against myeloma is unclear. Report > NICE, however, decided to back Enbrel and Raptiva for … Read more... | Press ReleasesAcambis reports positive data from trials of universal influenza A vaccine Acambis reports positive data from trials of universal influenza A vaccine Cambridge, UK and Cambridge, Massachusetts – 3 January 2008 – Acambis plc (Acambis) (LSE: ACM), a leading vaccine Read more... PRESS RELEASE: Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine Acambis Joins Forces With Sanofi Pasteur to Develop West Nile Virus Vaccine CAMBRIDGE, England and CAMBRIDGE, Massachusetts, November 1 - No Human Vaccine Currently Exists Against the West Nile Read more... PRESS RELEASE: FDA Approves ACAM2000 Vaccine for Protection Against Smallpox FDA Approves ACAM2000 Vaccine for Protection Against Smallpox CAMBRIDGE, England and CAMBRIDGE, Massachusetts, September 3 /PRNewswire-FirstCall/ -- Acambis plc (Acambis) , a leading vaccine Read more... |
Get more Acambis coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets